ENFORTUMAB- VEDOTIN- EJFV Home | Cancer | Solid Tumors | ENFORTUMAB- VEDOTIN- EJFV
ENFORTUMAB- VEDOTIN- EJFV Injection Description Composition Dosage Indications "PADCEV (enfortumab vedotin-ejfv) is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD1006). Conjugation takes place on cysteine residues that comprise the interchain disulfide bonds of the antibody to yield a product with a drug-to-antibody ratio of approximately 3.8:1. The molecular weight is approximately 152 kDa. PADCEV (enfortumab vedotin-ejfv) for injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous use. PADCEV is supplied as a 20 mg per vial and a 30 mg per vial and requires reconstitution with Sterile Water for Injection,"
Copyright © 2024 ImpoMed
Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API
Printed with Pdfcrowd.com